Chordoma: The nonsarcoma primary bone tumor

Oncologist

Volumn 12, Issue 11, 2007, Pages 1344-1350

  Chugh, Rashmi ^a   Tawbi, Hussein ^c   Lucas, David R ^a   Biermann, J Sybil ^b   Schuetze, Scott M ^a   Baker, Laurence H ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d Division of Hematology Oncology 3216 Cancer Center   (United States)

Author keywords

Bone tumors; Chordoma; Proton radiation

Indexed keywords

ALKALOID DERIVATIVE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; GEFITINIB; IMATINIB; RUBITECAN; THALIDOMIDE;

ATLANTOOCCIPITAL JOINT; BACK MUSCLE; BONE TUMOR; CANCER RELAPSE; CANCER SURVIVAL; CHORDOMA; CHROMOSOME ANALYSIS; CHROMOSOME STRUCTURE; CLINICAL FEATURE; DRUG ANTAGONISM; HUMAN; OCCIPITAL BONE; PRIORITY JOURNAL; PROTON THERAPY; RECURRENT DISEASE; REVIEW; SALVAGE THERAPY; SKULL BASE; SPHENOID; SURGICAL TECHNIQUE; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR RECURRENCE;

BONE NEOPLASMS; CHORDOMA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL ONCOLOGY; SKULL; TIME FACTORS; TREATMENT OUTCOME;

EID: 36849044547     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-11-1344     Document Type: Review

References (77)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. McMaster ML, Goldstein AM, Bromley CM et al. Chordoma: Incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11.
3. Mirra J, Nelson S, Della Rocca C et al. Chordoma. In: Fletcher CD, Unni K, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press, 2002:316-317.
4. Klingler L, Trammell R, Allan DG et al. Clonality studies in sacral chordoma. Cancer Genet Cytogenet 2006;171:68-71.
5. Baratti D, Gronchi A, Pennacchioli E et al. Chordoma: Natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003;10:291-296.
6. Pena CE, Horvat BL, Fisher ER. The ultrastructure of chordoma. Am J Clin Pathol 1970;53:544-551.
7. Higinbotham NL, Phillips RF, Farr HW et al. Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 1967;20:1841-1850.
8. Catton C, O'Sullivan B, Bell R et al. Chordoma: Long-term follow-up after radical photon irradiation. Radiother Oncol 1996;41:67-72.
9. Chambers PW, Schwinn CP. Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol 1979;72:765-776.
10. Casali PG, Stacchiotti S, Sangalli C et al. Chordoma. Current Opin Oncol 2007;19:367-370.
11. Riva P, Crosti F, Orzan F et al. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 2003;107:493-497.
12. Klingler L, Shooks J, Fiedler PN et al. Microsatellite instability in sacral chordoma. J Surg Oncol 2000;73:100-103.
13. Bridge JA, Pickering D, Neff JR. Cytogenetic and molecular cytogenetic analysis of sacral chordoma. Cancer Genet Cytogenet 1994;75:23-25.
14. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet 2003;143:1-31.
15. Eisenberg MB, Woloschak M, Sen C et al. Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surg Neurol 1997;47:156-160; discussion 160-161.
16. Butler MG, Sciadini M, Hedges LK et al. Chromosome telomere integrity of human solid neoplasms. Cancer Genet Cytogenet 1996;86:50-53.
17. Butler MG, Dahir GA, Hedges LK et al. Cytogenetic, telomere, and telomerase studies in five surgically managed lumbosacral chordomas. Cancer Genet Cytogenet 1995;85:51-57.
18. Boriani S, Bandiera S, Biagini R et al. Chordoma of the mobile spine: Fifty years of experience. Spine 2006;31:493-503.
19. Tzortzidis F, Elahi F, Wright D et al. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 2006;59:230-237; discussion 230-237.
20. Bergh P, Kindblom LG, Gunterberg B et al. Prognostic factors in chordoma of the sacrum and mobile spine: A study of 39 patients. Cancer 2000;88: 2122-2134.
21. Bosma JJ, Pigott TJ, Pennie BH et al. En bloc removal of the lower lumbar vertebral body for chordoma. Report of two cases. J Neurosurg 2001;94(2 suppl):284-291.
22. Bas T, Bas P, Prieto M et al. A lumbar chordoma treated with a wide resection. Eur Spine J 1994;3:115-117.
23. Heary RF, Vaccaro AR, Benevenia J et al. "En-bloc" vertebrectomy in the mobile lumbar spine. Surg Neurol 1998;50:548-556.
24. Hsu KY, Zucherman JF, Mortensen N et al. Follow-up evaluation of resected lumbar vertebral chordoma over 11 years: A case report. Spine 2000; 25:2537-2540.
25. Sundaresan N, Steinberger AA, Moore F et al. Indications and results of combined anterior-posterior approaches for spine tumor surgery. J Neurosurg 1996;85:438-446.
26. Fujita T, Kawahara N, Matsumoto T et al. Chordoma in the cervical spine managed with en bloc excision. Spine 1999;24:1848-1851.
27. Cotler HB, Cotler JM, Cohn HE et al. Intrathoracic chordoma presenting as a posterior superior mediastinal tumor. Spine 1983;8:781-786.
28. Keisch ME, Garcia DM, Shibuya RB. Retrospective long-term follow-up analysis in 21 patients with chordomas of various sites treated at a single institution. J Neurosurg 1991;75:374-377.
29. Rich TA, Schiller A, Suit HD et al. Clinical and pathologic review of 48 cases of chordoma. Cancer 1985;56:182-187.
30. Anegawa T, Rai M, Hara K et al. An unusual cervical chordoma: CT and MRI. Neuroradiology 1996;38:466-467.
31. Murphy JM, Wallis F, Toland J et al. CT and MRI appearances of a thoracic chordoma. Eur Radiol 1998;8:1677-1679.
32. Ducou le Pointe H, Brugieres P, Chevalier X et al. Imaging of chordomas of the mobile spine. J Neuroradiol 1991;18:267-276.
33. Smolders D, Wang X, Drevelengas A et al. Value of MRI in the diagnosis of non-clival, non-sacral chordoma. Skeletal Radiol 2003;32:343-350.
34. Bilsky MH, Yamada Y, Yenice KM et al. Intensity-modulated stereotactic radiotherapy of paraspinal tumors: A preliminary report. Neurosurgery 2004;54:823-830; discussion 830-831.
35. Noel G, Habrand JL, Jauffret E et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 2003;179:241-248.
36. Bjornsson J, Wold LE, Ebersold MJ et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer 1993;71:735-740.
37. Logroscino CA, Astolfi S, Sacchettoni G. Chordoma: Long-term evaluation of 15 cases treated surgically. Chir Organi Mov 1998;83:87-103.
38. Park L, Delaney TF, Liebsch NJ et al. Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006; 65:1514-1521.
39. Devin C, Chong PY, Holt GE et al. Level-adjusted perioperative risk of sacral amputations. J Surg Oncol 2006;94:203-211.
40. Cheng EY, Ozerdemoglu RA, Transfeldt EE et al. Lumbosacral chordoma. Prognostic factors and treatment. Spine 1999;24:1639-1645.
41. Habrand IL, Austin-Seymour M, Birnbaum S et al. Neurovisual outcome following proton radiation therapy. Int J Radiat Oncol Biol Phys 1989;16: 1601-1606.
42. Debus J, Hug EB, Liebsch NJ et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys 1997;39:967-975.
43. Pai HH, Thornton A, Katznelson L et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: Demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;49:1079-1092.
44. Slater JD, Austin-Seymour M, Munzenrider J et al. Endocrine function following high dose proton therapy for tumors of the upper clivus. Int J Radiat Oncol Biol Phys 1988;15:607-611.
45. Cummings BJ, Hodson DI, Bush RS. Chordoma: The results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys 1983;9:633-642.
46. Austin-Seymour M, Munzenrider J, Goitein M et al. Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 1989;70:13-17.
47. Igaki H, Tokuuye K, Okumura T et al. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 2004;60:1120-1126.
48. Noel G, Feuvret L, Calugaru V et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 2005;44:700-708.
49. Schulz-Ertner D, Nikoghosyan A, Thilmann C et al. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys 2004;58:631-640.
50. Terahara A, Niemierko A, Goitein M et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys 1999;45:351-358.
51. Weber DC, Rutz HP, Pedroni ES et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: The Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys 2005;63: 401-409.
52. Tai PT, Craighead P, Bagdon F. Optimization of radiotherapy for patients with cranial chordoma. A review of dose-response ratios for photon techniques. Cancer 1995;75:749-756.
53. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999;175(suppl 2):57-63.
54. Tai PT, Craighead P, Liem SK et al. Management issues in chordoma: A case series. Clin Oncol (R Coll Radiol) 2000;12:80-86.
55. Crockard HA, Cheeseman A, Steel T et al. A multidisciplinary team approach to skull base chondrosarcomas. J Neurosurg 2001;95:184-189.
56. Rhomberg W, Bohler FK, Novak H et al. A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlenther Onkol 2003; 179:249-253.
57. Crockard A. Chordomas and chondrosarcomas of the cranial base: Results and follow-up of 60 patients. Neurosurgery 1996;38:420.
58. Foweraker KL, Chantler HJ, Geater AR et al. Conformal versus IMRT for chordoma of the skull base and cervical spine. Clin Oncol (R Coll Radiol) 2007;19:S28-S29.
59. Hug EB, Loredo LN, Slater JD et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999;91:432-439.
60. Noel G, Habrand JL, Mammar H et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: The Centre de Protontherapie D'Orsay experience. Int J Radiat Oncol Biol Phys 2001;51:392-398.
61. Castro JR, Linstadt DE, Bahary JP et al. Experience in charged particle irradiation of tumors of the skull base: 1977-1992. Int J Radiat Oncol Biol Phys 1994;29:647-655.
62. Schoenthaler R, Castro JR, Petti PL et al. Charged particle irradiation of sacral chordomas. Int J Radiat Oncol Biol Phys 1993;26:291-298.
63. Berson AM, Castro JR, Petti P et al. Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: The Lawrence Berkeley Laboratory experience. Int J Radiat Oncol Biol Phys 1988; 15:559-565.
64. Fleming GF, Heimann PS, Stephens JK et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993;72:714-718.
65. Scimeca PG, James-Herry AG, Black KS et al. Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol 1996; 18:237-240.
66. Razis DV, Tsatsaronis A, Kyriazides I et al. Chordoma of the cervical spine treated with vincristine sulfate. J Med 1974;5:274-277.
67. McSweeney AJ, Sholl PR. Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordoma therapy. AMA Arch Surg 1959;79:152-155.
68. Azzarelli A, Quagliuolo V, Cerasoli S et al. Chordoma: Natural history and treatment results in 33 cases. J Surg Oncol 1988;37:185-191.
69. Chugh R, Dunn R, Zalupski MM et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005; 23:3597-3604.
70. Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer 2004;101:2086-2097.
71. Stacchiotti S, Ferrari S, Ferraresi V et al. Imatinib mesylate in advanced chordoma: A multicenter phase II study. J Clin Oncol 2007;25(18 suppl): Abstract 10003.
72. Tamborini E, Miselli F, Negri T et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006;12:6920-6928.
73. Burger H, den Bakker MA, Kros JM et al. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005;4:1270-1274.
74. Casali PG, Stacchiotti S, Grosso F et al. Adding cisplatin (CDDP) to imatinib (IM) re-establishes tumor response following secondary resistance to IM in advanced chordoma. J Clin Oncol 2007;25(18 suppl):Abstract 10038.
75. Weinberger PM, Yu Z, Kowalski D et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005;131: 707-711.
76. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006;29:572-574.
77. Schonegger K, Gelpi E, Prayer D et al. Recurrent and metastatic clivus chordoma: Systemic palliative therapy retards disease progression. Anticancer Drugs 2005;16:1139-1143.